METFORMIN AND DAPAGLIFLOZIN

DRUG2 trials

Sponsors

University Of Porto, University Of Porto, Centre Hospitalier Universitaire De Toulouse

Conditions

Heart failure with reduced ejection fractionheart failure

Phase 3

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

CompletedCTIS2022-502409-14-00

University Of Porto, University Of PortoHeart failure with reduced ejection fraction

Start: 2023-08-04End: 2025-07-31Target: 172Updated: 2025-05-27

Phase 4

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

Not yet recruitingCTIS2025-524395-30-00

Centre Hospitalier Universitaire De Toulouseheart failure

Target: 458Updated: 2026-05-29